- Home
- TRMD vs ADPT Comparison
TRMD vs ADPT Comparison
Compare TRMD & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMD
- ADPT
- Stock Information
- Founded
- TRMD 1889
- ADPT 2009
- Country
- TRMD United Kingdom
- ADPT United States
- Employees
- TRMD N/A
- ADPT N/A
- Industry
- TRMD Marine Transportation
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRMD Consumer Discretionary
- ADPT Health Care
- Exchange
- TRMD Nasdaq
- ADPT Nasdaq
- Market Cap
- TRMD 2.0B
- ADPT 2.0B
- IPO Year
- TRMD N/A
- ADPT 2019
- Fundamental
- Price
- TRMD $20.99
- ADPT $17.66
- Analyst Decision
- TRMD Buy
- ADPT Strong Buy
- Analyst Count
- TRMD 1
- ADPT 10
- Target Price
- TRMD $23.00
- ADPT $14.10
- AVG Volume (30 Days)
- TRMD 577.5K
- ADPT 2.0M
- Earning Date
- TRMD 11-06-2025
- ADPT 11-05-2025
- Dividend Yield
- TRMD 12.56%
- ADPT N/A
- EPS Growth
- TRMD N/A
- ADPT N/A
- EPS
- TRMD 3.31
- ADPT N/A
- Revenue
- TRMD $1,321,800,000.00
- ADPT $205,216,000.00
- Revenue This Year
- TRMD N/A
- ADPT $32.63
- Revenue Next Year
- TRMD N/A
- ADPT $16.31
- P/E Ratio
- TRMD $6.04
- ADPT N/A
- Revenue Growth
- TRMD N/A
- ADPT 21.60
- 52 Week Low
- TRMD $13.60
- ADPT $4.27
- 52 Week High
- TRMD $30.20
- ADPT $17.62
- Technical
- Relative Strength Index (RSI)
- TRMD 50.74
- ADPT 70.90
- Support Level
- TRMD $20.13
- ADPT $16.29
- Resistance Level
- TRMD $20.79
- ADPT $17.62
- Average True Range (ATR)
- TRMD 0.48
- ADPT 0.76
- MACD
- TRMD -0.01
- ADPT 0.22
- Stochastic Oscillator
- TRMD 62.17
- ADPT 94.76
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Engineering segment. The company derives maximum revenue from Tanker segment.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).